The effects of C-terminal truncation of receptor activity modifying proteins on the induction of amylin receptor phenotype from human CTb receptors

Regulatory Peptides

Volumn 145, Issue 1-3, 2008, Pages 65-71

  Udawela, Madhara ^b   Christopoulos, George ^a,b   Morfis, Maria ^a,b   Tilakaratne, Nanda ^a   Christopoulos, Arthur ^a   Sexton, Patrick M ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Amylin receptor phenotypes; Calcitonin receptors; Receptor activity modifying proteins

Indexed keywords

AMYLIN; AMYLIN RECEPTOR; CALCITONIN RECEPTOR; CALCITONIN RECEPTOR B; CYCLIC AMP; HORMONE RECEPTOR; RECEPTOR ACTIVITY MODIFYING PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOASSAY;

AMYLOID; ANIMALS; CERCOPITHECUS AETHIOPS; CYCLIC AMP; GENE DELETION; GLYCOSAMINOGLYCANS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; PHENOTYPE; RATS; RECEPTORS, CALCITONIN; RECEPTORS, PEPTIDE; SALMON;

RATTUS;

EID: 37349055186     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2007.08.003     Document Type: Article

References (25)

1. McLatchie L.M., Fraser N.J., Main M.J., Wise A., Brown J., Thompson N., Solari R., Lee M.G., and Foord S.M. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393 (1998) 333-339
2. Morfis M., Christopoulos A., and Sexton P.M. RAMPs: 5 years on, where to now?. Trends Pharmacol Sci 24 (2003) 596-601
3. Hay D.L., Poyner D.R., and Sexton P.M. GPCR modulation by RAMPs. Pharmacol Ther 109 (2006) 173-197
4. Christopoulos G., Perry K.J., Morfis M., Tilakaratne N., Gao Y., Fraser N.J., Main M.J., Foord S.M., and Sexton P.M. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Mol Pharmacol 56 (1999) 235-242
5. Muff R., Buhlmann N., Fischer J.A., and Born W. An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or-3. Endocrinology 140 (1999) 2924-2927
6. Poyner D.R., Sexton P.M., Marshall I., Smith D.M., Quirion R., Born W., Muff R., Fischer J.A., and Foord S.M. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev 54 (2002) 233-246
7. Hay D.L., Christopoulos G., Christopoulos A., Poyner D.R., and Sexton P.M. Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes. Mol Pharmacol 67 (2005) 1655-1665
8. Hay D.L., Christopoulos G., Christopoulos A., and Sexton P.M. Determinants of 1-piperidinecarboxamide, N-[2-[[5-Amino-l-[[4-(4-pyridinyl)-l-piperazinyl] carbonyl]pentyl]amino]-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl) (BIBN4096BS) affinity for calcitonin gene-related peptide and amylin receptors-the role of receptor activity modifying protein 1. Mol Pharmacol 70 (2006) 1984-1991
9. Fraser N.J., Wise A., Brown J., McLatchie L.M., Main M.J., and Foord S.M. The amino terminus of receptor activity modifying proteins is a critical determinant of glycosylation state and ligand binding of calcitonin receptor-like receptor. Mol Pharmacol 55 (1999) 1054-1059
10. Gorn A.H., Lin H.Y., Yamin M., Auron P.E., Flannery M.R., Tapp D.R., Manning C.A., Lodish H.F., Krane S.M., and Goldring S.R. Cloning, characterization, and expression of a human calcitonin receptor from an ovarian carcinoma cell line. J Clin Invest 90 (1992) 1726-1735
11. Gorn A.H., Rudolph S.M., Flannery M.R., Morton C.C., Weremowicz S., Wang T.Z., Krane S.M., and Goldring S.R. Expression of two human skeletal calcitonin receptor isoforms cloned from a giant cell tumour of bone. The first intracellular domain modulates ligand binding and signal transduction. J Clin Invest 95 (1995) 2680-2691
12. Moore E.E., Kuestner R.E., Stroop S.D., Grant F.J., Matthewes S.L., Brady C.L., Sexton P.M., and Findlay D.M. Functionally different isoforms of the human calcitonin receptor result from alternative splicing of the gene transcript. Mol Endocrinol 9 (1995) 959-968
13. Raggatt L.J., Evdokiou A., and Findlay D.M. Sustained activation of Erk1/2 MAPK and cell growth suppression by the insert-negative, but not the insert-positive isoform of the human calcitonin receptor. J Endocrinol 167 (2000) 93-105
14. Tilakaratne N., Christopoulos G., Zumpe E.T., Foord S.M., and Sexton P.M. Amylin receptor phenotypes derived from human calcitonin receptor/RAMP coexpression exhibit pharmacological differences dependent on receptor isoform and host cell environment. J Pharmacol Exp Ther 294 (2000) 61-72
15. Udawela M., Christopoulos G., Morfis M., Christopoulos A., Ye S., Tilakaratne N., and Sexton P.M. A critical role for the short intracellular C terminus in receptor activity modifying protein function. Mol Pharmacol 70 (2006) 1750-1760
16. Bomberger J.M., Parameswaran N., Hall C.S., Aiyar N., and Spielman W.S. Novel function for receptor activity-modifying proteins (RAMPs) in post-endocytic receptor trafficking. J Biol Chem 280 (2005) 9297-9307
17. Bomberger J.M., Spielman W.S., Hall C.S., Weinman E.J., and Parameswaran N. Receptor activity-modifying protein (RAMP) isoform-specific regulation of adrenomedullin receptor trafficking by NHERF-1. J Biol Chem 280 (2005) 23926-23935
18. Udawela M., Christopoulos G., Tilakaratne N., Christopoulos A., Albiston A., and Sexton P.M. Distinct receptor activity-modifying protein domains differentially modulate interaction with calcitonin receptors. Mol Pharmacol 69 (2006) 1984-1989
19. Steiner S., Muff R., Gujer R., Fischer J.A., and Born W. The transmembrane domain of receptor-activity-modifying protein 1 is essential for the functional expression of a calcitonin gene-related peptide receptor. Biochemistry 41 (2002) 11398-11404
20. Fitzsimmons T.J., Zhao X., and Wank S.A. The extracellular domain of receptor activity-modifying protein 1 is sufficient for calcitonin receptor-like receptor function. J Biol Chem 278 (2003) 14313-14320
21. Kuwasako K., Cao Y.N., Chu C.P., Iwatsubo S., Eto T., and Kitamura K. Functions of the cytoplasmic tails of the human receptor activity-modifying protein components of calcitonin gene-related peptide and adrenomedullin receptors. J Biol Chem 281 (2006) 7205-7213
22. Bhogal R., Smith D.M., and Bloom S.R. Investigation and characterization of binding sites for islet amyloid polypeptide in rat membranes. Endocrinology 130 (1992) 906-913
23. Kuwasako K., Shimekake Y., Masuda M., Nakahara K., Yoshida T., Kitaura M., Kitamura K., Eto T., and Sakata T. Visualization of the calcitonin receptor-like receptor and its receptor activity-modifying proteins during internalization and recycling. J Biol Chem 275 (2000) 29602-29609
24. Pham V., Wade J.D., Purdue B.W., and Sexton P.M. Spatial proximity between a photolabile residue in position 19 of salmon calcitonin and the amino terminus of the human calcitonin receptor. J Biol Chem 279 (2004) 6720-6729
25. Zumpe E.T., Tilakaratne N., Fraser N.J., Christopoulos G., Foord S.M., and Sexton P.M. Multiple ramp domains are required for generation of amylin receptor phenotype from the calcitonin receptor gene product. Biochem Biophys Res Commun 267 (2000) 368-372